Results 101 to 110 of about 26,042 (243)

Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib [PDF]

, 2011
Background/Aim. Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of Bcr-Abl positive chronic myeloid leukemia and become the standard of care for this disease.
Mačukanović-Golubović Lana, Ćojbašić Irena   +1 more
core   +1 more source

Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia

Haematologica, 2010
As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (
Asim F. Belgaumi, Ali Al-Shehri, Mouhab Ayas, Mohammed Al-Mahr, Amel Al-Seraihy, Ali Al-Ahmari, Hassan El-Solh   +6 more
doaj   +1 more source

Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. [PDF]

, 2014
BackgroundGastrointestinal stromal tumor (GIST) is the most common sarcoma and its treatment with imatinib has served as the paradigm for developing targeted anti-cancer therapies.
Babicky, Michele L, French, Randall P, Hoh, Carl K, Jaquish, Dawn V, Leonard, Stephanie Y, Lowy, Andrew M, Mose, Evangeline S, Peterson, Michael, Schwab, Richard, Sicklick, Jason K, Tang, Chih-Min   +10 more
core   +3 more sources

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate [PDF]

, 2018
Purpose: Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms of the gastrointestinal tract that are unresponsive to standard sarcoma chemotherapy.
Barghouth, G., Dizendorf, E., Goerres, G., Hany, T., Leyvraz, S., Luthi, F., Pestalozzi, B., Schnyder, P., Stupp, R., von Schulthess, G.   +9 more
core  

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia [PDF]

, 2017
Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved greatly. However, ~30-40% of patients develop resistance to imatinib therapy.
Bandyopadhyay, Shovik, Cheng, Ji-Xin, Li, Junjie, Oh, Stephen T, Traer, Elie, Tyner, Jeffrey W, Zhou, Amy   +6 more
core   +4 more sources

Mobilization of Ph chromosome‐negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate‐induced complete cytogenetic remission [PDF]

, 2003
Mark W. Drummond, David Marin, Richard E. Clark, Jenny Byrne, Tessa L. Holyoake, Anne Lennard, on behalf of the United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party   +6 more
openalex   +1 more source

Periorbital edema secondary to imatinib mesylate

Clinical Ophthalmology, 2010
Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland, George J Harocopos, Philip L Custer   +2 more
doaj  

Injectable Gamboge-Based In Situ Gel for Sustained Delivery of Imatinib Mesylate. [PDF]

Gels, 2023
Jitrangsri K, Khaing EM, Intaraphairot T, Phaechamud T, Mahadlek J.   +4 more
europepmc   +1 more source

Imatinib mesylate as a cause of acute liver failure [PDF]

, 2006
Timothy Cross, Catherine Bagot, B Portmann, Julia Wendon, D. Gillett   +4 more
openalex   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-940, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source